Literature DB >> 21748730

ProvenCare lung cancer: a multi-institutional improvement collaborative.

Mark R Katlic1, Matthew A Facktor, Scott A Berry, Karen E McKinley, Albert Bothe, Glenn D Steele.   

Abstract

Geisinger's ProvenCare™ Program (for elective coronary artery bypass surgery, total hip replacement, and others) has shown that the principles of reliability science, facilitated by a robust electronic health record and institutional commitment, allow the re-engineering of complicated clinical processes. This eliminates unwarranted variation and promotes the completion of evidence-based elements of care. It has not been established that ProvenCare can be generalized to other institutions. Now, under the auspices of the American College of Surgeons Commission on Cancer, ProvenCare has been adapted to a multi-institutional collaborative for the care of the patient with resectable lung cancer.
Copyright © 2011 American Cancer Society, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21748730     DOI: 10.3322/caac.20119

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  14 in total

1.  Improving lung cancer outcomes by improving the quality of surgical care.

Authors:  Raymond U Osarogiagbon; Thomas A D'Amico
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 2.  Is surgery still the best management option for early stage NSCLC?

Authors:  Aurel Ottlakan; Nicola Martucci; Gaetano Rocco
Journal:  Transl Lung Cancer Res       Date:  2014-06

3.  External validation of a prediction model for pathologic N2 among patients with a negative mediastinum by positron emission tomography.

Authors:  Farhood Farjah; Leah M Backhus; Thomas K Varghese; James P Manning; Aaron M Cheng; Michael S Mulligan; Douglas E Wood
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

4.  Quality indicators for the evaluation of patients with lung cancer.

Authors:  Peter J Mazzone; Anil Vachani; Andrew Chang; Frank Detterbeck; David Cooke; John Howington; Amos Dodi; Douglas Arenberg
Journal:  Chest       Date:  2014-09       Impact factor: 9.410

5.  TRAF4 is a critical molecule for Akt activation in lung cancer.

Authors:  Wei Li; Cong Peng; Mee-Hyun Lee; DoYoung Lim; Feng Zhu; Yang Fu; Ge Yang; Yuqiao Sheng; Lanbo Xiao; Xin Dong; WeiYa Ma; Ann M Bode; Ya Cao; Zigang Dong
Journal:  Cancer Res       Date:  2013-10-23       Impact factor: 12.701

6.  Gaps in Guideline-Concordant Use of Diagnostic Tests Among Lung Cancer Patients.

Authors:  Meghan R Flanagan; Thomas K Varghese; Leah M Backhus; Douglas E Wood; Michael S Mulligan; Aaron M Cheng; David R Flum; Farhood Farjah
Journal:  Ann Thorac Surg       Date:  2015-10-24       Impact factor: 4.330

7.  Trichosanthin enhances the antitumor effect of gemcitabine in non-small cell lung cancer via inhibition of the PI3K/AKT pathway.

Authors:  Naren Tuya; Yadi Wang; Lanmei Tong; Weishi Gao; Rong Yu; Liying Xue
Journal:  Exp Ther Med       Date:  2017-10-11       Impact factor: 2.447

8.  CDKN1A-interacting zinc finger protein 1 is a novel biomarker for lung squamous cell carcinoma.

Authors:  Xiaojun Zhou; Qiang Liu; Youichiro Wada; Lin Liao; Ju Liu
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

9.  Over-expression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of β-catenin.

Authors:  Ning Wu; Cong Liu; Chong Bai; Yi-Ping Han; William C S Cho; Qiang Li
Journal:  Int J Mol Sci       Date:  2013-05-23       Impact factor: 5.923

10.  MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China.

Authors:  Long-Feng Xu; Zhi-Ping Wu; Yan Chen; Qi-Shun Zhu; Shoeleh Hamidi; Roya Navab
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.